Vivek Subbiah: Our WHY is YOU!

Vivek Subbiah shared a post on LinkedIn:

”Clinical trials, Drug development unit dream team.

Yes! Our WHY is YOU!

Clinical trials are essential to advancing cancer treatment.

Let’s work together to increase awareness of clinical trial opportunities and encourage enrollment.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.